keyword
MENU ▼
Read by QxMD icon Read
search

DC vaccine

keyword
https://www.readbyqxmd.com/read/29769344/efficient-delivery-of-hcmv-t-cell-antigens-by-attenuated-sendai-virus-vectors
#1
Richard Kiener, Markus Fleischmann, Marian Alexander Wiegand, Niels A W Lemmermann, Christiane Schwegler, Christine Kaufmann, Angelique Renzaho, Simone Thomas, Eva Felder, Hans Helmut Niller, Benedikt Asbach, Ralf Wagner
Human Cytomegalovirus (HCMV) represents a major cause of clinical complications during pregnancy as well as immunosuppression and the licensing of a protective HCMV vaccine remains an unmet global need. Herein, we designed and validated novel Sendai virus (SeV) vectors delivering T cell immunogens IE-1 and pp65. To enhance vector safety, we used a replication-deficient strain (rdSeV) that infects target cells in a non-productive manner while retaining viral gene expression. In this study, we explored the impact that transduction with rdSeV has on human dendritic cells (DCs) by comparing it to the parental, replication-competent Sendai virus strain (rcSeV) as well as the poxvirus strain Modified Vaccinia Ankara (MVA)...
May 16, 2018: Journal of Virology
https://www.readbyqxmd.com/read/29764863/extracorporeal-photochemotherapy-drives-monocyte-to-dendritic-cell-maturation-to-induce-anti-cancer-immunity
#2
Alessandra Ventura, Aaron Vassall, Eve Robinson, Renata Filler, Douglas Hanlon, Katrina Meeth, Harib Ezaldein, Michael Girardi, Olga Sobolev, Marcus W Bosenberg, Richard L Edelson
Extracorporeal photochemotherapy (ECP) is a cancer immunotherapy for cutaneous T cell lymphoma (CTCL) operative in more than 350 centers worldwide. While its efficacy and favorable safety profile have driven its widespread use, elucidation of its underlying mechanism has been difficult. In this study, we identify the principal contributors to the anti-cancer immunotherapeutic effects of ECP, with the goal of enhancing potency and broadening applicability to additional malignancies. First, we scaled down the clinical ECP leukocyte-processing device to mouse size...
May 15, 2018: Cancer Research
https://www.readbyqxmd.com/read/29755693/exosomes-in-melanoma-a-role-in-tumor-progression-metastasis-and-impaired-immune-system-activity
#3
REVIEW
Marco Tucci, Francesco Mannavola, Anna Passarelli, Luigia Stefania Stucci, Mauro Cives, Franco Silvestris
Exosomes (Exo) are small vesicles produced by melanoma cells and the accessory cells of the tumor microenvironment. They emerge via both classical and direct pathways and actively participate in tumor colonisation of distant tissues. The proteins, nucleic acids, cytokines and growth factors engulfed by Exo are transferred to recipient cells, where they drive numerous functions required for the tumor escape from immune system control and tumor progression. By positively or negatively modulating immune cell properties, Exo provoke immune suppression and, in turn, defective dendritic cell (DC) functions...
April 17, 2018: Oncotarget
https://www.readbyqxmd.com/read/29754770/skewing-effect-of-sulprostone-on-dendritic-cell-maturation-compared-with-dinoprostone
#4
Jenny Bulgarelli, Laura Fiammenghi, Serena Cassan, Anna Maria Granato, Massimiliano Petrini, Elena Pancisi, Valentina Soldati, Francesco De Rosa, Laura Ridolfi, Angela Riccobon, Massimo Guidoboni
BACKGROUND: Dendritic cells (DCs) are the most efficient antigen-presenting cells and act at the center of the immune system owing to their ability to control both immune tolerance and immunity. In cancer immunotherapy, DCs play a key role in the regulation of the immune response against tumors and can be generated ex vivo with different cytokine cocktails. METHODS: We evaluated the feasibility of dinoprostone (PGE2 ) replacement with the molecular analog sulprostone, in our good manufacturing practice (GMP) protocol for the generation of DC-based cancer vaccine...
May 10, 2018: Cytotherapy
https://www.readbyqxmd.com/read/29752021/hyperthermic-treatment-at-56-%C3%A2-c-induces-tumour-specific-immune-protection-in-a-mouse-model-of-prostate-cancer-in-both-prophylactic-and-therapeutic-immunization-regimens
#5
Francesco De Sanctis, Sara Sandri, Matteo Martini, Marta Mazzocco, Alessandra Fiore, Rosalinda Trovato, Stefano Garetto, Davide Brusa, Stefano Ugel, Silvia Sartoris
Most active cancer immunotherapies able to induce a long-lasting protection against tumours are based on the activation of tumour-specific cytotoxic T lymphocytes (CTLs). Cell death by hyperthermia induces apoptosis followed by secondary necrosis, with the production of factors named "danger associated molecular pattern" (DAMP) molecules (DAMPs), that activate dendritic cells (DCs) to perform antigen uptake, processing and presentation, followed by CTLs cross priming. In many published studies, hyperthermia treatment of tumour cells is performed at 42-45 °C; these temperatures mainly promote cell surface expression of DAMPs...
May 8, 2018: Vaccine
https://www.readbyqxmd.com/read/29746488/development-of-endocytosis-degradative-activity-and-antigen-processing-capacity-during-gm-csf-driven-differentiation-of-murine-bone-marrow
#6
Adesola C Olatunde, Laura P Abell, Ashley E Landuyt, Elizabeth Hiltbold Schwartz
Dendritic cells (DC) are sentinels of the immune system, alerting and enlisting T cells to clear pathogenic threats. As such, numerous studies have demonstrated their effective uptake and proteolytic activities coupled with antigen processing and presentation functions. Yet, less is known about how these cellular mechanisms change and develop as myeloid cells progress from progenitor cells to more differentiated cell types such as DC. Thus, our study comparatively examined these functions at different stages of myeloid cell development driven by the GM-CSF...
2018: PloS One
https://www.readbyqxmd.com/read/29744371/proteomic-identification-of-heat-shock-induced-danger-signals-in-a-melanoma-cell-lysate-used-in-dendritic-cell-based-cancer-immunotherapy
#7
Fermín E González, Alexey Chernobrovkin, Cristián Pereda, Tamara García-Salum, Andrés Tittarelli, Mercedes N López, Flavio Salazar-Onfray, Roman A Zubarev
Autologous dendritic cells (DCs) loaded with cancer cell-derived lysates have become a promising tool in cancer immunotherapy. During the last decade, we demonstrated that vaccination of advanced melanoma patients with autologous tumor antigen presenting cells (TAPCells) loaded with an allogeneic heat shock- (HS-) conditioned melanoma cell-derived lysate (called TRIMEL) is able to induce an antitumor immune response associated with a prolonged patient survival. TRIMEL provides not only a broad spectrum of potential melanoma-associated antigens but also danger signals that are crucial in the induction of a committed mature DC phenotype...
2018: Journal of Immunology Research
https://www.readbyqxmd.com/read/29739853/mycobacterium-tuberculosis-ppe60-antigen-drives-th1-th17-responses-via-toll-like-receptor-2-dependent-maturation-of-dendritic-cells
#8
Haibo Su, Zhen Zhang, Zijian Liu, Baozhou Peng, Cong Kong, Honghai Wang, Zhi Zhang, Ying Xu
Targeting of Mycobacterium tuberculosis (MTB) PE/PPE antigens that induce type 1 helper T cell (Th1) and Th17 responses represents a crucial strategy for the development of tuberculosis (TB) vaccines. However, only few PE/PPE antigens induce these responses. Here, we sought to determine how the cell wall-associated antigen PPE60 (Rv3478) activates dendritic cell (DC) maturation and T-cell differentiation. We observed that PPE60 induces DC maturation by augmenting the protein expression of cluster of differentiation 80 (CD80) and CD86, and major histocompatibility complex (MHC) class I and MHC class II on the cell surface...
May 8, 2018: Journal of Biological Chemistry
https://www.readbyqxmd.com/read/29736404/-mycobacterium-tuberculosis-protein-rv3841-activates-dendritic-cells-and-contributes-to-a-t-helper-1-immune-response
#9
Seunga Choi, Han-Gyu Choi, Ki-Won Shin, Yong Woo Back, Hye-Soo Park, Jae Hwi Lee, Hwa-Jung Kim
The attenuated vaccine Mycobacterium bovis BCG (Bacille Calmette Guerin) has limited protective efficacy against TB. The development of more effective TB vaccines has focused on the mycobacterial antigens that cause strong T helper 1 (Th1) responses. Mtb protein Rv3841 (bacterioferritin B; BfrB) is known to play a crucial role in the growth of Mtb. Nonetheless, it is unclear whether Rv3841 can induce protective immunity against Mtb. Here, we studied the action of Rv3841 in maturation of dendritic cells (DCs) and its engagement in the development of T-cell immunity...
2018: Journal of Immunology Research
https://www.readbyqxmd.com/read/29731862/synergistic-anti-tumor-effects-of-dasatinib-and-dendritic-cell-vaccine-on-metastatic-breast-cancer-in-a-mouse-model
#10
Ningning Song, Hulin Guo, Jia Ren, Suhong Hao, Xinchao Wang
Immunotherapy is currently considered as one of the major anti-tumor modalities, but its efficacy is limited. Dasatinib could improve the expansion and recruitment of cluster of differentiation (CD) 8+ T cells and natural killer (NK) cells to the tumor microenvironment. The present study aimed to evaluate the synergistic anti-tumor effects of dasatinib with dendritic cell (DC) vaccine in metastatic breast cancer. Dasatinib with DC vaccine was administered to mice inoculated with 4T1 breast cancer cells. Thereafter, tumor volume was measured every other day...
May 2018: Oncology Letters
https://www.readbyqxmd.com/read/29728403/vaccine-therapy-in-hematologic-malignancies
#11
David Avigan, Jacalyn Rosenblatt
Immune based therapy has emerged as a paradigm shift in cancer therapy with dramatic responses observed in previously incurable disease. Cancer vaccines are being developed to disrupt tumor-associated tolerance and activate and selectively expand tumor specific lymphocytes within the native effector cell repertoire while maintaining immune regulatory protection against auto-immunity. While individual antigen approaches result in immune response with a suggestion of clinical effect in some settings, broader efficacy may be dependent on presentation of multiple antigens that capture clonal diversity presented in the context of functionally potent antigen presenting cells...
May 4, 2018: Blood
https://www.readbyqxmd.com/read/29724512/initial-phase-i-iia-trial-results-of-an-autologous-tumor-lysate-particle-loaded-dendritic-cell-tlpldc-vaccine-in-patients-with-solid-tumors
#12
Garth S Herbert, Timothy J Vreeland, Guy T Clifton, Julia M Greene, Doreen O Jackson, Mark O Hardin, Diane F Hale, John S Berry, Pauline Nichol, Sook Yin, Xianzhong Yu, Thomas E Wagner, George E Peoples
INTRODUCTION: Tumor vaccines use various strategies to generate immune responses, commonly targeting generic tumor-associated antigens. The tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine is produced from DC loaded with autologous tumor antigens, creating a patient-specific vaccine. Here, we describe initial phase I/IIa trial results. METHODS: This trial includes patients with any stage solid tumors, ECOG ≤1, and >4 months life-expectancy. A personalized vaccine is created using 1 mg of tumor and 120 ml blood (to isolate DC)...
April 30, 2018: Vaccine
https://www.readbyqxmd.com/read/29712687/cross-talk-between-t-cells-and-hematopoietic-stem-cells-during-adoptive-cellular-therapy-for-malignant-glioma
#13
Tyler J Wildes, Adam Grippin, Kyle A Dyson, Brandon M Wummer, David J Damiani, Rebecca S Abraham, Catherine Flores, Duane A Mitchell
PURPOSE: Adoptive T cell immunotherapy (ACT) has emerged as a viable therapeutic for peripheral and central nervous system (CNS) tumors. In peripheral cancers, optimal efficacy of ACT is reliant on dendritic cells (DCs) in the tumor microenvironment. However, the CNS is largely devoid of resident migratory DCs to function as antigen-presenting cells during immunotherapy. Herein, we demonstrate that cellular interactions between adoptively-transferred tumor-reactive T cells and bone marrow-derived HSPCs lead to the generation of potent intratumoral DCs within the CNS compartment...
April 30, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29696308/role-of-mda5-and-interferon-i-in-dendritic-cells-for-t-cell-expansion-by-anti-tumor-peptide-vaccines-in-mice
#14
Hussein Sultan, Juan Wu, Takumi Kumai, Andres M Salazar, Esteban Celis
Cytotoxic T lymphocytes (CTLs) are effective components of the immune system capable of destroying tumor cells. Generation of CTLs using peptide vaccines is a practical approach to treat cancer. We have previously described a peptide vaccination strategy that generates vast numbers of endogenous tumor-reactive CTLs after two sequential immunizations (prime-boost) using poly-ICLC adjuvant, which stimulates endosomal toll-like receptor 3 (TLR3) and cytoplasmic melanoma differentiation antigen 5 (MDA5). Dendritic cells (DCs) play an important role not only in antigen presentation but are critical in generating costimulatory cytokines that promote CTL expansion...
April 25, 2018: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/29695694/-maturation-and-antigen-loading-protocols-influence-activity-of-anticancer-dendritic-cells
#15
Zh K Nazarkina, A Zajakina, P P Laktionov
The practical use of dendritic cell-based vaccines in anticancer therapy is limited by a lack of standards for dendritic cell (DC) generation, as well as standard procedures for controlling their activation and the technique of DC loading with nucleic acids encoding tumor antigens. Analyzing the currently available data, the most promising cocktails for DC maturation were selected and a comparative study of the cocktails and time of maturation on the capacity of DC to activate T-cell immune response has been performed...
March 2018: Molekuliarnaia Biologiia
https://www.readbyqxmd.com/read/29692776/interleukin-15-cultured-dendritic-cells-enhance-anti-tumor-gamma-delta-t-cell-functions-through-il-15-secretion
#16
Heleen H Van Acker, Sébastien Anguille, Hans De Reu, Zwi N Berneman, Evelien L Smits, Viggo F Van Tendeloo
Dendritic cell (DC) vaccination can be an effective post-remission therapy for acute myeloid leukemia (AML). Yet, current DC vaccines do not encompass the ideal stimulatory triggers for innate gamma delta (γδ) T cell anti-tumor activity. Promoting type 1 cytotoxic γδ T cells in patients with AML is, however, most interesting, considering these unconventional T cells are primed for rapid function and exert meaningful control over AML. In this work, we demonstrate that interleukin (IL)-15 DCs have the capacity to enhance the anti-tumoral functions of γδ T cells...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29682201/molecular-signatures-associated-with-tumor-specific-immune-response-in-melanoma-patients-treated-with-dendritic-cell-based-immunotherapy
#17
Tamara García-Salum, Andrea Villablanca, Franziska Matthäus, Andrés Tittarelli, Mauricio Baeza, Cristián Pereda, M Alejandra Gleisner, Fermín E González, Mercedes N López, Jörg D Hoheisel, Johannes Norgauer, Peter J Gebicke-Haerter, Flavio Salazar-Onfray
Purpose: We previously showed that autologous dendritic cells (DCs) loaded with an allogeneic heat shock (HS)-conditioned melanoma cell-derived lysate, called TRIMEL, induce T-cell-mediated immune responses in stage IV melanoma patients. Importantly, a positive delayed-type hypersensitivity (DTH) reaction against TRIMEL after vaccination, correlated with patients prolonged survival. Furthermore, we observed that DTH reaction was associated with a differential response pattern reflected in the presence of distinct cell subpopulations in peripheral blood...
March 30, 2018: Oncotarget
https://www.readbyqxmd.com/read/29666934/quo-vadis-do-immunotherapies-have-a-role-in-glioblastoma
#18
REVIEW
Sylvia C Kurz, Patrick Y Wen
PURPOSE OF REVIEW: More effective therapies for glioblastoma are urgently needed. Immunotherapeutic strategies appear particularly promising and are therefore intensively studied. This article reviews the current understanding of the immunosuppressive glioblastoma microenvironment, discusses the rationale behind various immunotherapies, and outlines the findings of several recently published clinical studies. RECENT FINDINGS: The results of CheckMate-143 indicated that nivolumab is not superior to bevacizumab in patients with recurrent glioblastoma...
April 18, 2018: Current Treatment Options in Neurology
https://www.readbyqxmd.com/read/29662482/targeting-mycobacterium-tuberculosis-antigens-to-dendritic-cells-via-the-dc-specific-icam3-grabbing-nonintegrin-receptor-induces-strong-t-helper-1-immune-responses
#19
Lis Noelia Velasquez, Philipp Stüve, Maria Virginia Gentilini, Maxine Swallow, Judith Bartel, Nils Yngve Lycke, Daniel Barkan, Mariana Martina, Hugo D Lujan, Hakan Kalay, Yvette van Kooyk, Tim D Sparwasser, Luciana Berod
Tuberculosis remains a major global health problem and efforts to develop a more effective vaccine have been unsuccessful so far. Targeting antigens (Ags) to dendritic cells (DCs) in vivo has emerged as a new promising vaccine strategy. In this approach, Ags are delivered directly to DCs via antibodies that bind to endocytic cell-surface receptors. Here, we explored DC-specific-ICAM3-grabbing-nonintegrin (DC-SIGN) targeting as a potential vaccine against tuberculosis. For this, we made use of the hSIGN mouse model that expresses human DC-SIGN under the control of the murine CD11c promoter...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29649855/a-salmonella-typhi-ghost-induced-by-the-e-gene-of-phage-%C3%AF-x174-stimulates-dendritic-cells-and-efficiently-activates-the-adaptive-immune-response
#20
Gayeon Won, Seong Kug Eo, Sang-Youel Park, Jin Hur, John Hwa Lee
We previously genetically engineered a Salmonella Typhi bacterial ghost (STG) as a novel inactivated vaccine candidate against typhoid fever. The underlying mechanism employed by the ghost to stimulate the adaptive immune response remains to be investigated. In this study, we aimed to evaluate the immunostimulatory effect of STG on mouse bone marrow-derived dendritic cells (BMDCs) and its activation of the adaptive immune response in vitro . Immature BMDCs were stimulated with STG, which efficiently stimulated maturation events in BMDCs, as indicated by up-regulated expression of CD40, CD80, and MHC-II molecules on CD11+ BMDCs...
April 12, 2018: Journal of Veterinary Science
keyword
keyword
8566
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"